TD Cowen analyst Ritu Baral maintained a Buy rating on Insmed (INSM – Research Report) today and set a price target of $98.00. The ...

RNAi therapeutics company Alnylam Pharmaceuticals, Inc. (ALNY) announced Wednesday the submission of its supplemental New Drug ...

Shares of Soleno Therapeutics SLNO jumped 9.1% on Tuesday and continued to gain another 4.1% during the after-market hours ...

The FDA in 2022 approved Amvuttra to treat adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis, a rare debilitating disease that damages nerves, and analysts have predicted ...

Scholar Rock yesterday reported that its experimental treatment for spinal muscular atrophy succeeded in a Phase 3 trial, ...

The time to re-enter the RNAi revolution is now,” said Robert Nelsen, the managing director of Arch, which led the Series A funding round for City Therapeutics.

Ultragenyx Pharmaceutical RARE announced that the FDA has granted the Breakthrough Therapy designation to its investigational candidate, setrusumab (UX143), as a treatment to reduce the risk of ...

City Therapeutics, based in Cambridge, is developing new medicines that use RNA interference, or RNAi, to silence genes and ...

A new RNAi biotech is breaking ground with $135 million and John Maraganore, Ph.D., holding the key to the city. | A new RNAi ...

Taking the mat is Judo Bio, an up-and-coming biotech armed with $100 million to develop oligonucleotide medicines targeting ...

The Cambridge, Massachusetts-based biotech is using what it calls ligand-siRNA conjugates to reach drug targets in the kidney, which historically have been difficult to reach with RNA therapies.

Judo Bio, a biotechnology company pioneering oligonucleotide medicines delivered to the kidney, today announced the company's launch and $100 million in initial financing, including seed financing and ...